LON:ABZA

Abzena (ABZA) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
15.75
15.75
52-Week Range
N/A
Volume
100 shs
Average Volume
220,500 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ABZA stock logo

About Abzena Stock (LON:ABZA)

Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

ABZA Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ABZA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abzena and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. William John Edward Burt (Age 50)
    CEO & Exec. Director
  • Prof. Sunil Shaunak
    Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D.
    Co-Founder
  • Prof. Steve Brocchini Ph.D.
    Co-Founder
  • Dr. Jim Mills
    Sr. VP of Technical Operations

ABZA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Abzena own?
How do I buy shares of Abzena?

Shares of ABZA stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ABZA) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners